GlassScriptPhysician profile
John Dahunsi
NPI 1386378735
$3,243.99
in general payments reported to CMS, 2019-2025
17 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.20 · 2023: $813 · 2024: $1,297 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206 · Education: $9.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.40 |
| Education | $9.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.23 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $508.95 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $484.22 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Corium, LLC | $228.94 | 2024-2025 | Azstarys |
| Lundbeck LLC | $210.85 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $200.95 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $145.04 | 2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $135.19 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $126.20 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $108.41 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $94.53 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.32 | 2023 | |
| Axsome Therapeutics, INC. | $51.40 | 2024-2025 | Sunosi, Auvelity |
| Neos Therapeutics, LP | $38.19 | 2024 | Adzenys Xr-Odt |
| Indivior INC. | $28.20 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $17.20 | 2024 | Relexxii |
| Noven Therapeutics, LLC | $16.17 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dahunsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.